Skip to content

Study · Non-randomized trial · n = 44 · 2016

3 results

Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.

Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, Linares J, Lundström E, Purcea D, Cassorla F

Journal of pediatric endocrinology & metabolism : JPEM1 Nov 2016Cited by 29 (Europe PMC)

PMID26887034 (opens in a new tab)DOI10.1515/jpem-2015-0376 (opens in a new tab)PepBankPUB-26887034
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with central precocious puberty, triptorelin suppressed LH to prepubertal levels in most patients at month 6.

    In plain wordsIn children with central precocious puberty, triptorelin suppressed LH to prepubertal levels in most patients at month 6.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePrepubertal LH at month 6
    Study

    n = 44

    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    22.5 mg · intramuscular · 48 weeksAs given in this study (human).

    Measurements

    Patients with LH suppression
    41 patients
    month 6
    LH suppression
    93.2%
    month 6
    Stimulated LH threshold
    ≤ 5 IU/L
    prepubertal

    Source sentences

    Summary
    Forty-one patients (93.2%) showed pre-pubertal LH levels (stimulated LH ≤5 IU/L) at month 6 and maintained LH suppression through month 12.
    4 context sentences
    Summary · context
    This was an international, non-comparative phase III study over 48 weeks.
    Summary · context
    Forty-four treatment naïve patients (39 girls and five boys) aged at treatment start 2-8 years for girls and 2-9 years for boys with an advancement of bone age over chronological age ≥1 year were to be included.
    Summary · context
    Triptorelin was administered im twice at an interval of 24 weeks.
    Summary · context
    The current triptorelin 22.5 mg 6-month formulation is approved for prostate cancer therapy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with central precocious puberty, LH suppression with triptorelin exceeded 93% at each assessment and reached 97.7% at month 12.

    In plain wordsIn children with central precocious puberty, triptorelin suppressed LH in 97.7% at month 12.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseLH suppression through month 12
    Study

    n = 44

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    22.5 mg · intramuscular · 48 weeksAs given in this study (human).

    Measurements

    LH suppression
    > 93%
    each time point
    LH suppression
    97.7%
    month 12

    Source sentences

    Summary
    The percentage of patients with LH suppression exceeded 93% at each time point and reached 97.7% at month 12.
    4 context sentences
    Summary · context
    This was an international, non-comparative phase III study over 48 weeks.
    Summary · context
    Forty-four treatment naïve patients (39 girls and five boys) aged at treatment start 2-8 years for girls and 2-9 years for boys with an advancement of bone age over chronological age ≥1 year were to be included.
    Summary · context
    Triptorelin was administered im twice at an interval of 24 weeks.
    Summary · context
    The current triptorelin 22.5 mg 6-month formulation is approved for prostate cancer therapy.
  3. 03HumanNon-randomized trialSafety outcome

    In children with central precocious puberty receiving triptorelin, no unexpected drug-related adverse events were reported.

    In plain wordsIn children with central precocious puberty receiving triptorelin, no unexpected drug-related adverse events were reported.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableUnexpected drug-related adverse events
    Study

    n = 44

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    22.5 mg · intramuscular · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    No unexpected drug-related adverse events were reported.
    4 context sentences
    Summary · context
    This was an international, non-comparative phase III study over 48 weeks.
    Summary · context
    Forty-four treatment naïve patients (39 girls and five boys) aged at treatment start 2-8 years for girls and 2-9 years for boys with an advancement of bone age over chronological age ≥1 year were to be included.
    Summary · context
    Triptorelin was administered im twice at an interval of 24 weeks.
    Summary · context
    The current triptorelin 22.5 mg 6-month formulation is approved for prostate cancer therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.